Literature DB >> 7889018

Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis.

M Owsianowski1, H Gollnick, W Siegert, R Schwerdtfeger, C E Orfanos.   

Abstract

A 43-year-old woman who had undergone allogeneic bone marrow transplant for chronic myeloid leukemia developed chronic GVHD. Despite cyclosporine A and low-dose glucocorticoids and later concomittent PUVA-therapy, chronic GVHD with severe sclerodermatous manifestations including joint contracture and liver damage progressed. The Karnofsky performance score dropped to under 50%. Extracorporeal photopheresis (ECP) instead of PUVA-therapy was started. To our knowledge, we here report the first case of successful treatment of extensive chronic GVHD with ECP.

Entities:  

Mesh:

Year:  1994        PMID: 7889018

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

Review 1.  Management of graft-versus-host disease in paediatric bone marrow transplant recipients.

Authors:  M Zecca; F Locatelli
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  Extracorporeal Photopheresis: A Case of Immunotherapy Ahead of Its Time.

Authors:  Pablo Augusto Vieyra-Garcia; Peter Wolf
Journal:  Transfus Med Hemother       Date:  2020-05-27       Impact factor: 3.747

3.  Guidelines on the use of extracorporeal photopheresis.

Authors:  R Knobler; G Berlin; P Calzavara-Pinton; H Greinix; P Jaksch; L Laroche; J Ludvigsson; P Quaglino; W Reinisch; J Scarisbrick; T Schwarz; P Wolf; P Arenberger; C Assaf; M Bagot; M Barr; A Bohbot; L Bruckner-Tuderman; B Dreno; A Enk; L French; R Gniadecki; H Gollnick; M Hertl; C Jantschitsch; A Jung; U Just; C-D Klemke; U Lippert; T Luger; E Papadavid; H Pehamberger; A Ranki; R Stadler; W Sterry; I H Wolf; M Worm; J Zic; C C Zouboulis; U Hillen
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-01       Impact factor: 6.166

4.  Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.

Authors:  James W Hart; Lisa H Shiue; Elizabeth J Shpall; Amin M Alousi
Journal:  Ther Adv Hematol       Date:  2013-10

5.  Extracorporeal Photochemotherapy as a Challenging Treatment for Cutaneous T-Cell Lymphoma, Acute and Chronic Graft-versus-Host Disease, Organ Rejection and T-Lymphocyte-Mediated Autoimmune Diseases.

Authors:  Paolo Perseghin
Journal:  Transfus Med Hemother       Date:  2007-12-21       Impact factor: 3.747

6.  Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD.

Authors:  Madan Jagasia; Christof Scheid; Gérard Socié; Francis Ayuketang Ayuk; Johanna Tischer; Michele L Donato; Árpád Bátai; Heidi Chen; Sheau-Chiann Chen; Thomas Chin; Henri Boodée; Ghaith Mitri; Hildegard T Greinix
Journal:  Blood Adv       Date:  2019-07-23

7.  Previously Activated Psoralen: A Possible Novel Format of Psoralen Used in the Treatment of Graft-versus-host Disease.

Authors:  X Hu; L Qian; X Chen; J Shen
Journal:  West Indian Med J       Date:  2015-01-27       Impact factor: 0.171

Review 8.  Extracorporeal photo-apheresis for the treatment of steroid-resistant graft versus host disease.

Authors:  Kristin Baird; Alan S Wayne
Journal:  Transfus Apher Sci       Date:  2009-10-09       Impact factor: 1.764

9.  Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation.

Authors:  P J Shaughnessy; B J Bolwell; K van Besien; M Mistrik; A Grigg; A Dodds; H M Prince; S Durrant; O Ilhan; D Parenti; J Gallo; F Foss; J Apperley; M-J Zhang; M M Horowitz; S Abhyankar
Journal:  Bone Marrow Transplant       Date:  2009-11-16       Impact factor: 5.483

Review 10.  Extracorporeal Photopheresis in Graft-versus-Host Disease.

Authors:  Beatrice Drexler; Andreas Buser; Laura Infanti; Gregor Stehle; Joerg Halter; Andreas Holbro
Journal:  Transfus Med Hemother       Date:  2020-05-19       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.